K
Karine Lheritier
Researcher at Novartis
Publications - 50
Citations - 1507
Karine Lheritier is an academic researcher from Novartis. The author has contributed to research in topics: Canakinumab & Placebo. The author has an hindex of 13, co-authored 44 publications receiving 1272 citations. Previous affiliations of Karine Lheritier include Department of Urology, University of Virginia.
Papers
More filters
Journal ArticleDOI
Two randomized trials of canakinumab in systemic juvenile idiopathic arthritis
Nicolino Ruperto,Hermine I. Brunner,Pierre Quartier,Tamás Constantin,Nico M Wulffraat,Gerd Horneff,Riva Brik,Liza J McCann,Ozgur Kasapcopur,Lidia Rutkowska-Sak,Rayfel Schneider,Yackov Berkun,Inmaculada Calvo,Muferet Erguven,Laurence Goffin,Michael Hofer,Tilmann Kallinich,Sheila Knupp Feitosa de Oliveira,Yosef Uziel,Stefania Viola,Kiran Nistala,Carine Wouters,Rolando Cimaz,Manuel A. Ferrandiz,Berit Flatø,M.L. Gamir,Isabelle Koné-Paut,Alexei A. Grom,Bo Magnusson,Seza Ozen,Flavio Sztajnbok,Karine Lheritier,Ken Abrams,Dennis Y. Kim,Alberto Martini,Alberto Martini,Daniel J. Lovell +36 more
TL;DR: These two phase 3 studies show the efficacy and safety of canakinumab in systemic JIA with active systemic features, and among the 100 patients who underwent randomization in the withdrawal phase, the risk of flare was lower among patients who continued to receive canakinUMab than among those who were switched to placebo.
Journal ArticleDOI
Canakinumab for the Treatment of Autoinflammatory Recurrent Fever Syndromes
Fabrizio De Benedetti,Marco Gattorno,Jordi Anton,Eldad Ben-Chetrit,Joost Frenkel,Hal M. Hoffman,Isabelle Koné-Paut,Helen J. Lachmann,Seza Ozen,Anna Simon,Andrew Zeft,Inmaculada Calvo Penades,Michel Moutschen,Pierre Quartier,Ozgur Kasapcopur,Anna Shcherbina,Michael Hofer,Philip J. Hashkes,Jeroen Van der Hilst,Ryoki Hara,Segundo Bujan-Rivas,Tamás Constantin,Ahmet Gül,Avi Livneh,Paul A. Brogan,Marco Cattalini,Laura Obici,Karine Lheritier,A. Speziale,Guido Junge +29 more
TL;DR: In this trial, canakinumab was effective in controlling and preventing flares in patients with colchicine‐resistant familial Mediterranean fever, mevalonate kinase deficiency, and TRAPS.
Journal ArticleDOI
Sustained remission of symptoms and improved health-related quality of life in patients with cryopyrin-associated periodic syndrome treated with canakinumab: results of a double-blind placebo-controlled randomized withdrawal study
Isabelle Koné-Paut,Helen J. Lachmann,Jasmin B Kuemmerle-Deschner,Eric Hachulla,Kieron S. Leslie,Richard Mouy,Alberto Ferreira,Karine Lheritier,N Patel,R Preiss,Philip N. Hawkins +10 more
TL;DR: Canakinumab, 150 mg, 8-weekly, induced rapid and sustained remission of symptoms in patients with CAPS, accompanied by substantial improvements in HRQoL, and therapy was generally well tolerated.
Journal ArticleDOI
Rate and Clinical Presentation of Macrophage Activation Syndrome in Patients With Systemic Juvenile Idiopathic Arthritis Treated With Canakinumab.
Alexei A. Grom,Norman T. Ilowite,Virginia Pascual,Hermine I. Brunner,Alberto Martini,Daniel J. Lovell,Nicolino Ruperto,K. Leon,Karine Lheritier,Ken Abrams +9 more
TL;DR: In pivotal trials, canakinumab has been shown to be effective in the treatment of systemic juvenile idiopathic arthritis, but reported adverse events have included macrophage activation syndrome (MAS).
Journal ArticleDOI
Dose response with darifenacin, a novel once-daily M3 selective receptor antagonist for the treatment of overactive bladder: results of a fixed dose study.
TL;DR: Darifenacin is effective and well tolerated in the treatment of OAB, with 7.5 and 15 mg doses offering flexibility of dosing for optimal treatment outcome.